UK alleges GSK paid off competitors to delay drugs

by Danica Kirka

Britain's competition watchdog accused GlaxoSmithKline on Friday of paying off competitors to delay launches of their own versions of GSK's best-selling antidepressant, Seroxat.

The Office of Fair Trading alleges made deals that infringed competition law with Alpharma Ltd., Generics (UK) Ltd and Norton Healthcare Ltd. over the supply of paroxetine, which GSK sold under the name Seroxat. The watchdog said GSK's conduct amounted to an abuse of its in the same market.

"The introduction of can lead to strong competition on price, which can drive savings for the (), to the benefit of patients and, ultimately, taxpayers," said Ann Pope, the senior director of services, infrastructure and public markets at the OFT. "It is therefore particularly important that the OFT fully investigates concerns that independent generic entry may have been delayed in this case."

The OFT alleges that when the generic drug companies tried to compete with Seroxat, GSK challenged them with allegations that their products would infringe upon GSK patents. To settle the disputes, the generic companies would receive payment from GSK, the OFT claimed.

The drug company said in a statement that it would fully cooperate with the investigation, which it said stemmed from activities that occurred between 2001 and 2004.

The company also said that the inquiry examines issues investigated by two European Commission inquiries, neither of which resulted in sanction.

" supports fair competition and we very strongly believe that we acted within the law," the statement said.

The company said it had noted the OFT's plan to issue what is known as a Statement of Objections.

Pope said the OFT would carefully consider what the companies said in response to their accusations before deciding whether they should be sanctioned. If The OFT decides the "pay for delay" agreements were unacceptable, it can impose fines of up to 30 percent of revenue over the timeframe in which the violations occurred.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Drug firm GSK fined $2.6 million for collusion

Oct 24, 2011

South Korea's anti-trust agency has fined drugmaker GlaxoSmithKline three billion won ($2.6 million) for conspiring with a Seoul rival over the sale of drugs, an official said Monday.

GSK unveils expansion plans in India, Nigeria

Nov 26, 2012

British drugmaker GlaxoSmithKline said it intends to increase its holdings in its Indian and Nigerian divisions, as part of a long-term strategy to expand into emerging markets, in a statement on Monday.

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

rsklyar
1 / 5 (1) Apr 29, 2013
How British swindlers are stealing in their cheating journal Nature Materials at https://connect.i...sr/blogs (Impertinent cheating ... & A robbery ...)

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.